APA (7th ed.) Citation

Martín, M., Chan, A., Dirix, L., O'Shaughnessy, J., Hegg, R., Manikhas, A., . . . Delaloge, S. (2017). A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Oxford University Press.

Chicago Style (17th ed.) Citation

Martín, M., et al. A Randomized Adaptive Phase II/III Study of Buparlisib, a Pan-class I PI3K Inhibitor, Combined with Paclitaxel for the Treatment of HER2- Advanced Breast Cancer (BELLE-4). Oxford University Press, 2017.

MLA (9th ed.) Citation

Martín, M., et al. A Randomized Adaptive Phase II/III Study of Buparlisib, a Pan-class I PI3K Inhibitor, Combined with Paclitaxel for the Treatment of HER2- Advanced Breast Cancer (BELLE-4). Oxford University Press, 2017.